English Overview
The discussion will covers several aspects of GLP-1 RA therapy including comparison to other first injectable therapies for T2DM, safety and efficacy of once-a-week GLP-1 RA.
This Activity for
- Resident / Fellow
- Physician
What I will learn?
Understand increased cardiovascular Risks with Type 2 Diabetes patients.
Understand different cardiovascular trials design and patient population distribution.
Understand the difference between primary and secondary CV protection.
Understand the results of recent CV trials for Once-weekly dulaglutide and its implications on T2D patients.
Understand different cardiovascular trials design and patient population distribution.
Understand the difference between primary and secondary CV protection.
Understand the results of recent CV trials for Once-weekly dulaglutide and its implications on T2D patients.
Speakers 1 Distinguished Speakers
Additional items to the activity
| Optional Details | Type | Fee |
|---|---|---|
|
Cardiovascular Benefits of Once-a-Week GLP-1 RA Option for T2DM Certificate
Accreditation |
Certificate | Free |
VAT 15% Included
